AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10588564
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg/mL, n = 73
Trial: 10588564
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/mL, n = 71
Trial: 6685512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate tape (1 piece, 40 mg/tape)
Trial: 6685512
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate tape (2-3 pieces, 40 mg/tape)
Trial: 31368588
Drug: Drug filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug filling group (triamcinolone acetonide clotrimazole injected into the external auditory canal)
Trial: 31368588
Drug: Drug smearing
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug smearing group (smearing antifungal cream once per day)
Trial: 23905372
Drug: Pengyan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pengyan Pill (PP) - 10 g each time, thrice daily for 14 consecutive days
Trial: 23905372
Drug: Azithromycin -
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin - 10 g each day for 7 consecutive days
Trial: 23905372
Drug: Pengyan Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pengyan Pill (PP)
Trial: 19234829
Drug: Individualized recruitment
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized recruitment maneuver (RM) with pressure equal to 15 ml x real body weight/Cdyn + PEEP for 15 s
Trial: 15277416
Drug: Pioglitazone (30-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30-mg tablet of Actos)
Trial: 15277416
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with GLP-1 and pioglitazone
Trial: 15277416
Drug: Saline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline therapy
Trial: 23954500
Drug: 6.5mg prasterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5mg prasterone (DHEA) administered intravaginally daily
Trial: 18090394
Drug: Differential adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differential adherence (any antiretroviral medication)
Trial: 10774095
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg every 21 days)
Trial: 3912026
Drug: Ibuprofen 2400
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 2400 mg (given in two or four equally divided daily doses)
Trial: 3912026
Drug: Ibuprofen (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (twice daily)
Trial: 3912026
Drug: Ibuprofen (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (four times daily)
Trial: 31301627
Drug: Sunlight plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunlight plus conventional vitamin D supplement (400IU/d)
Trial: 31301627
Drug: Sunlight exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunlight exposure (7-14 h/week) plus conventional vitamin D supplement (400IU/d)
Trial: 24813646
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg ATP daily for 4 weeks
Trial: 20211294
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg twice daily (2.5 mg twice daily in selected patients)
Trial: 22818021
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 to 324 mg daily
Trial: 16307657
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg per week
Trial: 12114351
Drug: Beclomethasone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 100 microg/d plus zafirlukast 20 mg bid
Trial: 12114351
Drug: Beclomethasone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 100 microg/d plus theophylline 200 to 300 mg bid
Trial: 10439754
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 0.1% ropivacaine with 1 microgram/mL sufentanil (R + S)
Trial: 10439754
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of 0.1% ropivacaine without sufentanil (R)
Trial: 8560534
Drug: Ivermectin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (5 doses distributed every 6 months)
Trial: 2518436
Drug: Various procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Various procedures concerning the site of implantation and treatment of exocrine function
Trial: 61224
Drug: Tolmetin sodium
RxNorm normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolmetin sodium (800-1600 mg daily for 12 weeks)
Trial: 61224
Drug: Tolmetin sodium
RxNorm normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolmetin sodium (400-2400 mg daily for 2 years)
Trial: 28244804
Drug: Pharmacogenetic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic testing integrated into medication therapy management services
Trial: 16456408
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor + ranitidine
Trial: 16456408
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor + placebo
Trial: 12207595
Drug: Isotretinoin gel
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin gel 0.05%
Trial: 9707349
Drug: Epogam (evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epogam (evening primrose oil) - 6 capsules in the morning and 6 capsules in the evening
Trial: 359254
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oxyphenbutazone 3-times daily
Trial: 27073000
Drug: HR-ADM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR-ADM plus standard of care (SOC) applied weekly for up to 12 weeks
Trial: 15517057
Drug: Psychodynamic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic group treatment (PGT)
Trial: 30049729
Drug: Bubble nCPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bubble nCPAP and nebulised surfactant (200 mg/kg: poractant alfa)
Trial: 25979614
Drug: 17-hydroxyprogesterone caproate
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-hydroxyprogesterone caproate (250 mg weekly intramuscular injections)
Trial: 21312264
Drug: ONO-5334 50
RxNorm normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-5334 50 mg twice daily
Trial: 21719717
Drug: ONO-5334 100
RxNorm normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-5334 100 mg once daily
Trial: 21719717
Drug: ONO-5334 300
RxNorm normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-5334 300 mg once daily
Trial: 12763981
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction in inhaled corticosteroid dose (stepdown)
Trial: 12763981
Drug: No alteration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alteration to inhaled corticosteroid dose (control)
Trial: 10678632
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg oral slow-release theophylline (250 mg if <70 kg) taken twice daily
Trial: 10678632
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablet taken twice daily
Trial: 9362433
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg) as a 4-hour infusion every 4 weeks for 21 cycles in addition to antimyeloma chemotherapy
Trial: 8383639
Drug: Gorging pattern
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gorging pattern (2 meals daily)
Trial: 8383639
Drug: Nibbling pattern
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nibbling pattern (3 to 5 meals daily)
Trial: 3535005
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice daily) for 6 months
Trial: 3535005
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment with ranitidine
Trial: 25316451
Drug: Daily emotional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emotional monitoring
Trial: 22389428
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 mg/day) plus lifestyle counselling
Trial: 19531931
Drug: DPSGC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 50 mg
Trial: 20187842
Drug: DPSGC 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPSGC 25 mg and 50 mg
Trial: 16274480
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg prophylactic and 4 mg postoperative IV) and Diclofenac potassium (50 mg oral before and after surgery)
Trial: 16274480
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (50 mg oral before and after surgery)
Trial: 11950484
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketanserin given as intravenous boluses every 10 min
Trial: 11950484
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ketanserin given as intravenous boluses every 20 min
Trial: 10468799
Drug: Maxacalcitol 25
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol 25 microg/g
Trial: 10468799
Drug: Maxacalcitol (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxacalcitol (6, 12.5, 25, and 50 microg/g)
Trial: 10468799
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg/g
Trial: 8678261
Drug: metoclopramide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 0.1 mg.kg‐1
Trial: 8678261
Drug: metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 0.2 mg.kg‐1
Trial: 8678261
Drug: prochlorperazine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prochlorperazine 0.1 mg.kg‐1
Trial: 8678261
Drug: prochlorperazine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prochlorperazine 0.2 mg.kg‐1
Trial: 2149047
Drug: Teicoplanin (T)
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (T) 6 mg/kg/d and Fluconazole (F) 3 mg/kg/d
Trial: 2149047
Drug: Teicoplanin (T)
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (T) 10 mg/kg/d, Ceftriaxone (C) 50 mg/kg/d, and Amikacin (A) 15 mg/kg/d
Trial: 379841
Drug: 768 mg
RxNorm normalized name: butyl chloride 1768 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 768 mg chlormethiazole
Trial: 28724331
Drug: Balanites aegyptiaca
RxNorm normalized name: BALANITES AEGYPTIACA SEED OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanites aegyptiaca (BE) capsules (400mg/day) for 8 weeks
Trial: 26669547
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 6 mm-long implants
Trial: 26669547
Drug: 10 mm-long
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm-long implants
Trial: 24424409
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg, 3-month loading phase with monthly injections, followed by a 12-month maintenance phase.
Trial: 22940437
Drug: EHCSS-K6 (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHCSS-K6 (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Trial: 22940437
Drug: EHCSS-K3 (3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHCSS-K3 (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Trial: 17138937
Drug: Argatroban (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (350 microg/kg intravenous bolus followed by 25 microg/kg per minute infusion)
Trial: 17138937
Drug: Enoxaparin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.75 mg/kg, intravenous bolus)
Trial: 11318292
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin A (CsA)
Trial: 2965231
Drug: Isradipine (5.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5.1 mg twice daily)
Trial: 29535504
Drug: HTX-019 (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-019 (130 mg) IV over 30 min
Trial: 29535504
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg) IV over 30 min
Trial: 25065855
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg weekly for 5 weeks)
Trial: 17411338
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) including protease inhibitor or non-nucleoside reverse transcriptase inhibitor
Trial: 12221873
Drug: N2O:O2 (70:30)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2O:O2 (70:30) + phentanyl (0.1 ml boluses every 20 min)
Trial: 10076584
Drug: Food label
RxNorm normalized name: Take With Food Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food label education program (9 weekly group sessions)
Trial: 7367779
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate aerosol (BDA)
Trial: 17255296
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy in the metastatic setting
Trial: 17255296
Drug: Neoadjuvant strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant strategies integrating aggressive surgical intervention with systemic therapy
Trial: 15119639
Drug: Early start
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early start dialysis (10-14 mL/min/1.73 m2)
Trial: 15119639
Drug: Late start
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late start dialysis (5-7 mL/min/1.73 m2)
Trial: 11268891
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid 500 mg twice a day for 7.5 days
Trial: 11268891
Drug: Pristinamycin 1
RxNorm normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin 1 g twice a day for 10 days
Trial: 3935853
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (cephalosporin treatment alone: cefotaxime, cefazolin)
Trial: 3935853
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two or three antibiotics
Trial: 3935853
Drug: Wider antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wider antibiotic spectrum
Trial: 29486504
Drug: Hippotherapy (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (once to twice weekly for 16 to 20 weeks, mean: 17 treatments)
Trial: 29486504
Drug: Hippotherapy (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (early treatment group)
Trial: 25312315
Drug: Platelet rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma (5 mL in two applications)
Trial: 25312315
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (1 gr every 8 hours for 30 days)
Trial: 17660520
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1 ng ml(‐1)
Trial: 17660520
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 3 ng ml(‐1)
Trial: 17660520
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 5 ng ml(‐1)
Trial: 14732596
Drug: High-dose glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose glycine (0.8 g/kg/day)
Trial: 10730723
Drug: Preventive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive oral hygiene program including instruction of the carers and implementation of a recall program for professional oral hygiene care
Trial: 10730723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preventive oral hygiene program)
Trial: 8831317
Drug: 1.73% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.73% lidocaine with 10 micrograms/mL of clonidine (Group C10)
Trial: 8831317
Drug: 1.73% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.73% lidocaine (Group L)
Trial: 8831317
Drug: 1.73% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.73% lidocaine with 20 micrograms/mL clonidine (Group C20)
Trial: 1279289
Drug: Terbutaline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (5 mg three times daily)
Trial: 1279289
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg twice daily) with Terbutaline
Trial: 30706247
Drug: T-DM1 (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1 (3.6 mg/kg q3w, 2.4 mg/kg qw)
Trial: 30706247
Drug: T-DM1 (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1 (2.4 mg/kg qw)
Trial: 21937808
Drug: Laparoscopic splenectomy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic splenectomy, perisoph‐agogastric devascularization and endoscopic variceal ligation (combination group)
Trial: 19155351
Drug: Percutaneous intramuscular
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous intramuscular electrical stimulation for hand opening (n = 13)
Trial: 15019537
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (500 mg/day)
Trial: 15019537
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenofibrate and Vitamin E
Trial: 9188228
Drug: Dental implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental implants
Trial: 12500879
Drug: Natural teeth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural teeth and implants
Trial: 9141204
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms Engerix-B vaccine
Trial: 9141204
Drug: 40 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 micrograms Engerix-B vaccine
Trial: 3436158
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g aztreonam
Trial: 30796598
Drug: New peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New peanut allergen treatment
Trial: 30412221
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with TPF (docetaxel, cisplatin, 5-FU omitted in subsequent patients) followed by radiotherapy (69.6 Gy)
Trial: 30412221
Drug: Cetuximab added
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab added to induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Trial: 30412221
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with TPF followed by radiotherapy (69.6 Gy)
Trial: 22377815
Drug: Propranolol LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol LA (240 mg/day)
Trial: 22377815
Drug: Topiramate alone
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate alone (50-100 mg/day)
Trial: 19615827
Drug: TSST administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSST administered prior to compassion meditation training